FDA warns doctors of counterfeit Botox

Federal regulators have warned more than 350 medical practices that Botox they may have received from a Canadian supplier is unapproved and could be counterfeit or unsafe.

The Food and Drug Administration said in a letter sent last month and released last week that batches of the wrinkle treatment shipped by suppliers owned by pharmacy Canada Drugs have not been approved by the FDA and that the agency cannot assure their effectiveness or their safety.

The FDA said Canada Drugs was previously tied to shipping unapproved and counterfeit cancer drugs.

The agency warns doctors about of buying drugs from sources other than licensed U.S. pharmacies. This is the fifth warning the agency has made this year about foreign suppliers providing unapproved drugs.

More information: 1.usa.gov/R7jKiR

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA cracks down on untested cold medicines

Mar 02, 2011

(AP) -- The Food and Drug Administration says it will remove roughly 500 unapproved cold and allergy medications from the market as part of an ongoing campaign cracking down on ineffective prescription medications.

FDA warning public of risks of online pharmacies

Sep 28, 2012

The Food and Drug Administration is warning the public that most Internet pharmacies are fraudulent, selling drugs that likely are counterfeit and could harm or even kill people.

FDA cracks down on unapproved narcotic painkillers

Mar 31, 2009

(AP) -- The government ordered 14 unapproved narcotic painkillers off the market Tuesday, prescription versions of potent morphine, hydromorphone and oxycodone. The Food and Drug Administration told nine manufacturers to ...

FDA acts against unapproved colchicine

Feb 06, 2008

The U.S. Food and Drug Administration said it will take action against companies marketing unapproved injectable colchicine, a drug used to treat gout.

FDA sends Procter & Gamble a warning

Sep 18, 2007

The U. S. Food and Drug Administration has warned the Procter & Gamble Co. about claims it makes for its Vicks Early Defense Foaming Hand Sanitizer.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

kochevnik
1 / 5 (1) Dec 25, 2012
Standard corporfascism. FDA revolving door with big pharma